TY - JOUR T1 - The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial JF - BMJ Open Diabetes Research & Care JO - BMJ Open Diab Res Care DO - 10.1136/bmjdrc-2014-000079 VL - 3 IS - 1 SP - e000079 AU - Andreea Soare AU - Rossella Del Toro AU - Elena Roncella AU - Yeganeh Manon Khazrai AU - Silvia Angeletti AU - Laura Dugo AU - Sara Fallucca AU - Lucia Fontana AU - Maria Altomare AU - Valeria Formisano AU - Francesca Capata AU - Rosaria Gesuita AU - Silvia Manfrini AU - Francesco Fallucca AU - Mario Pianesi AU - Paolo Pozzilli AU - for the MADIAB Group Y1 - 2015/03/01 UR - http://drc.bmj.com/content/3/1/e000079.abstract N2 - Introduction Current guidelines for the management of type 2 diabetes (T2D) emphasize diet as essential therapy. However, the effect of diet on systemic inflammation remains unclear. We investigated the effects of consuming a macrobiotic Ma-Pi 2 diet versus a standard recommended diet (control diet) on markers of inflammation in patients with T2D.Methods This was a post hoc analysis of the MADIAB trial, a 21-day randomized controlled trial conducted in 51 patients (25 males and 26 females) with T2D. Patients were randomized 1:1 to the Ma-Pi 2 macrobiotic diet or a control diet based on dietary guidelines for T2D. Biological antioxidant potential of plasma and circulating levels of high-sensitivity C reactive protein, interleukin-6, tumor necrosis factor-α, and insulin-like growth factor-1 were assessed.Results After 21 days on the Ma-Pi 2 or control diet, markers of inflammation were reduced in both groups. The antioxidant potential of plasma improved significantly in the Ma-Pi group. A significant reduction in insulin growth factor-1 was observed in the Ma-Pi group versus control group (p<0.001).Conclusions Findings of this post hoc analysis demonstrated that the Ma-Pi 2 diet is a safe dietary strategy to reduce levels of the markers of insulin resistance and inflammation, compared with baseline values, in the short term. Furthermore, the Ma-Pi 2 diet was superior to the control diet in reducing insulin growth factor-1 and may be beneficial for patients with T2D.Trial registration number Current Controlled Trials ISRCTN10467793. ER -